{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:05:01Z","timestamp":1789718701597,"version":"4.0.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a 12-month randomized, double-blind, placebo-controlled trial, we have studied the effects of intranasal salmon calcitonin (SCT) on bone mineral density (BMD) and biochemical markers of bone turnover. Twenty-eight men with idiopathic osteoporosis aged 27-74 years (mean, 52.4 years) were randomized to receive either nasal SCT (200 IU) or a nasal placebo daily for a period of 1 year. All the men received a daily supplement of 0.5 g of calcium. The men who received SCT had a mean (\u00b1SEM) increase in BMD of 7.1 \u00b1 1.7% at the lumbar spine. In contrast, the men who received the placebo had an increase of 2.4 \u00b1 1.5% (p &amp;gt; 0.05) for the comparison with baseline. The increase in lumbar BMD in the calcitonin group was significantly greater than that in the placebo group (p &amp;lt; 0.05). There were no significant changes in the femoral neck, trochanter, or Ward's triangle relative to both baseline and placebo after 12 months. Treatment with nasal SCT resulted in a significantly pronounced suppression of bone resorption markers (urinary deoxypyridinoline [DPD], type I cross-linked N-telopeptide [NTX], and type I cross-linked C-telopeptide [CTX]) and to a lesser extent in bone formation markers (serum bone-specific alkaline phosphatase [BALP], osteocalcin [OC], serum C-terminal procollagen type I extension peptides [PICP], and serum N-terminal procollagen type I extension peptides [PINP]), whereas the placebo did not. Therapy was tolerated well and there were no treatment-related adverse events. We conclude that intranasal SCT (200 IU daily) is safe and effective in increasing lumbar BMD and reducing bone turnover in men with idiopathic osteoporosis.<\/jats:p>","DOI":"10.1359\/jbmr.2002.17.3.521","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T05:08:32Z","timestamp":1146114512000},"page":"521-527","source":"Crossref","is-referenced-by-count":84,"title":["A Randomized Trial of Nasal Spray Salmon Calcitonin in Men With Idiopathic Osteoporosis: Effects on Bone Mineral Density and Bone Markers"],"prefix":"10.1093","volume":"17","author":[{"given":"G. P.","family":"Dr. Trovas","sequence":"first","affiliation":[{"name":"Laboratory for the Research of Musculoskeletal System, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. P.","family":"Lyritis","sequence":"additional","affiliation":[{"name":"Laboratory for the Research of Musculoskeletal System, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Galanos","sequence":"additional","affiliation":[{"name":"Laboratory for the Research of Musculoskeletal System, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Raptou","sequence":"additional","affiliation":[{"name":"Laboratory for the Research of Musculoskeletal System, University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Constantelou","sequence":"additional","affiliation":[{"name":"Hormormonological Laboratory, Public Hospital, Saint Panteleimonas, Piraeus, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"2024013019102687400_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/91.2.71","article-title":"Management of male osteoporosis: Report of the UK Consensus Group","volume":"91","author":"Eastell","year":"1998","journal-title":"QJM"},{"key":"2024013019102687400_bib2","first-page":"S1;S370","article-title":"Aetiology in male osteoporosis","volume":"12","author":"Trovas","year":"1997","journal-title":"J Bone Miner Res"},{"key":"2024013019102687400_bib3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/rheumatology\/34.10.936","article-title":"Aetiology and presenting symptoms in male osteoporosis","volume":"34","author":"Peris","year":"1995","journal-title":"Br J Rheumatol"},{"key":"2024013019102687400_bib4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-123-6-199509150-00010","article-title":"Severe osteoporosis in men","volume":"123","author":"Kelepouris","year":"1998","journal-title":"Ann Intern Med"},{"key":"2024013019102687400_bib5","first-page":"133","volume-title":"Osteoporosis. Etiology, Diagnosis and Management","author":"Melton","year":"1998"},{"key":"2024013019102687400_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ageing\/26.5.359","article-title":"Effect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fractures","volume":"26","author":"Anderson","year":"1997","journal-title":"Age Ageing"},{"issue":"Suppl 5","key":"2024013019102687400_bib7","first-page":"451","article-title":"Treatment of osteoporosis (osteopenia) in adult men with disodium etidronate","volume":"54","author":"Lozano-Tonkin","year":"1994","journal-title":"Calcified Tissue Int"},{"key":"2024013019102687400_bib8","first-page":"140","volume-title":"Current Research in Osteoporosis and Bone Mineral Measurement IV: Bath Conference on Osteoporosis and Bone Mineral Measurement","author":"Dargie","year":"1996"},{"key":"2024013019102687400_bib9","first-page":"1507","author":"Devogelaer","year":"1990"},{"key":"2024013019102687400_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0169-6009(89)90095-0","article-title":"Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD","volume":"5","author":"Valkema","year":"1989","journal-title":"Bone Miner"},{"key":"2024013019102687400_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"2024013019102687400_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s001980050047","article-title":"Avoidance of vertebral dose intermittent monofluorophosphate","volume":"8","author":"Ringe","year":"1998","journal-title":"Osteoporos Int"},{"key":"2024013019102687400_bib13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/BF00298742","article-title":"Prevention of bone loss in early non-surgical and non-osteoporotic high turnover patients with salmon calcitonin: The role of biochemical markers in monitoring high turnover patients under calcitonin treatment","volume":"56","author":"Lyritis","year":"1995","journal-title":"Calcif Tissue Int"},{"key":"2024013019102687400_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF00297179","article-title":"Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study","volume":"55","author":"Overgaard","year":"1994","journal-title":"Calcif Tissue Int"},{"key":"2024013019102687400_bib15","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0002-9343(99)80344-1","article-title":"A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss","volume":"98","author":"Reginster","year":"1995","journal-title":"Am J Med"},{"key":"2024013019102687400_bib16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","article-title":"Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study","volume":"305","author":"Overgaard","year":"1992","journal-title":"BMJ"},{"key":"2024013019102687400_bib17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF02556148","article-title":"Effect of different doses of nasal salmon calcitonin on bone mass","volume":"48","author":"Thamsborg","year":"1991","journal-title":"Calcif Tissue Int"},{"key":"2024013019102687400_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"2024013019102687400_bib19","first-page":"237","volume-title":"Calcitonin","author":"Agrawal","year":"1981"},{"key":"2024013019102687400_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0140-6736(93)92555-8","article-title":"Bone density at various sites for prediction of hip fractures","volume":"341","author":"Cummings","year":"1993","journal-title":"Lancet"},{"key":"2024013019102687400_bib21","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"2024013019102687400_bib22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650111021","article-title":"Bone resorption markers predict hip fracture risk in elderly women: The EPIDOS prospective study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019102687400_bib23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bmj.312.7029.482","article-title":"Case-control analysis of bone resorption markers, disability, hip fracture risk: The Rotterdam study","volume":"312","author":"Van Daele","year":"1996","journal-title":"BMJ"},{"issue":"Suppl 1","key":"2024013019102687400_bib24","first-page":"S102","article-title":"Changes in BMD substantially underestimate the anti-fracture effect of alendronate and other antiresorptive drugs","volume":"11","author":"Cummings","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2024013019102687400_bib25","first-page":"S174","article-title":"The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis","volume":"23","author":"Ensrud","year":"1998","journal-title":"Bone"},{"key":"2024013019102687400_bib26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/8756-3282(95)00447-5","article-title":"Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis","volume":"18","author":"Thamsborg","year":"1996","journal-title":"Bone"},{"key":"2024013019102687400_bib27","first-page":"341","volume-title":"Osteoporosis","author":"Seeman","year":"1996"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2Fjbmr.2002.17.3.521","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/17\/3\/521\/56471868\/5650170318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/17\/3\/521\/56471868\/5650170318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:04:46Z","timestamp":1710342286000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/17\/3\/521-527\/7592566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3,1]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,12,2]]},"published-print":{"date-parts":[[2002,3,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.2002.17.3.521","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2002,3,1]]},"published":{"date-parts":[[2002,3,1]]}}}